Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
April 16 2014 - 8:00AM
Business Wire
Dyax Corp. (NASDAQ: DYAX) announced today the appointment of
Todd Bazemore as Executive Vice President and Chief Commercial
Officer. Mr. Bazemore will be responsible for leading Dyax’s
commercial organization which currently markets KALBITOR®
(ecallantide) for the treatment of acute attacks of hereditary
angioedema (HAE) in patients 12 years of age and older.
Mr. Bazemore joins Dyax as a pharmaceutical executive with 20
years of leadership and commercial operating experience in sales,
marketing and managed markets. He most recently served as Vice
President, Managed Markets at Sunovion Pharmaceuticals, Inc.
(formerly Sepracor). Prior to this, he served as Vice President of
Sales and Marketing leading the Sunovion Respiratory Business Unit
where he was responsible for the overall strategic direction and
financial performance of the unit which generated $680 million in
annual revenue. During his time at Sunovion, Mr. Bazemore held
several roles of increasing responsibility in marketing and sales
leadership including Vice President of Sales for the Pinnacle Sales
Team, which was responsible for promoting OMNARIS®, as well as
LUNESTA®, one of the most successful pharmaceutical product
launches in the U.S. He also went on to build and oversee multiple
sales and marketing teams responsible for several successful new
product launches including BROVANA® and XOPENEX®.
“Todd is a senior healthcare executive with two decades of
commercial experience in both primary care and specialty markets,
which makes him ideally suited to lead our commercial team,” said
Gustav Christensen, President and Chief Executive Officer of Dyax.
“His strong track record of strategic leadership, operational
execution, and launching and developing brands will be highly
valuable as we aim to grow our KALBITOR business and as we develop
plans for how to optimize the value of DX-2930 which is currently
in clinical development.”
Mr. Bazemore stated, “It's a privilege to join the Dyax team
during this important time as we continue to successfully
commercialize KALBITOR and develop our future plans for DX-2930.
I'm excited about the opportunity we have to truly help both the
patients suffering from HAE and the physicians that treat
them.”
About Dyax
Dyax is a fully integrated biopharmaceutical company focused on
the discovery, development and commercialization of novel
biotherapeutics for unmet medical needs. The Company currently
markets KALBITOR® for the treatment of acute attacks of hereditary
angioedema (HAE) in patients 12 years of age and older. Dyax is
also developing DX-2930, a fully human monoclonal antibody
inhibitor of plasma kallikrein, for the prophylactic treatment of
HAE. Additionally, the Company has developed a biomarker assay that
detects activated plasma kallikrein in blood and is being used for
internal research and development efforts, including the
exploration and identification of other plasma-kallikrein-mediated
indications beyond HAE.
Both KALBITOR and DX-2930 were identified using Dyax's patented
phage display technology. Dyax has broadly licensed this technology
and has a portfolio of product candidates being developed by our
licensees, which it refers to as the Licensing and Funded Research
Portfolio (LFRP). The Company is eligible to receive future
milestones and/or royalties dependent upon the development and
commercialization of these candidates.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full
prescribing information, please visit www.KALBITOR.com.
Disclaimer
This press release contains forward-looking statements.
Statements that are not historical facts are based
on Dyax's current expectations, beliefs, assumptions,
estimates, forecasts and projections about the industry and markets
in which Dyax competes. The statements contained in this
release are not guarantees of future performance and involve
certain risks, uncertainties and assumptions, which are difficult
to predict. Therefore, actual outcomes and results may differ
materially from what is expressed in such forward-looking
statements. Important factors which may affect future performance
include the risks that: DX-2930 may not show sufficient therapeutic
effect or an acceptable safety profile in clinical trials or could
take longer to gain regulatory approval than Dyax expects
or may never gain approval; others may develop products superior to
KALBITOR or DX-2930; KALBITOR and/or DX-2930 may not gain market
acceptance; Dyax is dependent on the expertise, effort,
priorities and contractual obligations of third parties in the
manufacture, marketing, sales and distribution of KALBITOR and
DX-2930; and other risk factors described or referred to in Item
1A, "Risk Factors" in Dyax's most recent Annual Report on
Form 10-K and other periodic reports filed with the Securities
and Exchange Commission. Dyax cautions investors not to place
undue reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this
release, and Dyax undertakes no obligations to update or
revise these statements, except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered marks
of Dyax Corp.
Dyax Corp.Jennifer Robinson, 617-250-5741Associate Director,
Investor Relations and Corporate
Communicationsjrobinson@dyax.com
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dyax (NASDAQ:DYAX)
Historical Stock Chart
From Sep 2023 to Sep 2024